MeSH D051436 - chronic renal insufficiency
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D051437:Renal insufficiency
0 Companies
0 Drugs
Success rate
D002908:Chronic disease
0 Companies
0 Drugs
Success rate
D051436:Â
Chronic renal insufficiency
D007676:Chronic kidney failure
D000092702:Chronic kidney diseases of uncertain etiology
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Akebia Therapeutics | Vadadustat | Vafseo |  | 2023-04-24 |  |  |
| AstraZeneca | Dapagliflozin | Edistride |  | 2015-11-09 |  |  |
| Dapagliflozin | Forxiga |  | 2012-11-11 |  |  | |
| Bayer | Finerenone | Kerendia |  | 2022-02-16 |  |  |
| Boehringer Ingelheim | Empagliflozin | Jardiance |  | 2014-05-22 |  |  |
| Viatris | Dapagliflozin | Dapagliflozin Viatris |  | 2023-03-24 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
81%54/67
Phase 2
70%75/107
Phase 3
54%62/115
Approved: 1Overall Success rate: 30%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use